Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Histone Modification02:32

Histone Modification

16.2K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
16.2K
Survey Safety01:28

Survey Safety

413
Surveying near highways, rough terrain, or power lines involves significant risks. Working along highways is particularly dangerous and requires the use of warning signs and flagmen. It is safest to avoid working directly on roads and use offsets whenever possible. When highway work is unavoidable, it must follow all safety guidelines. Surveyors should wear bright clothing, such as orange reflective vests, to ensure visibility to motorists, coworkers, and hunters. In construction zones, wearing...
413
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

9.5K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
9.5K
Receiver Operating Characteristic Plot01:15

Receiver Operating Characteristic Plot

492
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
492

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rib Cross-Sectional Mineralized Area in Early Pleistocene Hominins: Insights From the Homo antecessor and H. erectus s. l. Fossil Record.

American journal of biological anthropology·2026
Same author

ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.

ESMO open·2026
Same author

Dostarlimab and niraparib in primary advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025
Same author

Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Related Experiment Video

Updated: Feb 10, 2026

Surface Electromyographic Biofeedback as a Rehabilitation Tool for Patients with Global Brachial Plexus Injury Receiving Bionic Reconstruction
09:14

Surface Electromyographic Biofeedback as a Rehabilitation Tool for Patients with Global Brachial Plexus Injury Receiving Bionic Reconstruction

Published on: September 28, 2019

12.1K

Safety and dose modification for patients receiving niraparib.

J S Berek1, U A Matulonis2, U Peen3

  • 1Department of Obstetrics & Gynecology, Stanford Women's Cancer Center, Stanford University School of Medicine, Stanford, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 17, 2018
PubMed
Summary
This summary is machine-generated.

Niraparib maintenance therapy for ovarian cancer requires dose adjustments in many patients. Lower starting doses of 200mg may benefit patients with lower baseline body weight or platelet counts, improving safety without compromising efficacy.

More Related Videos

Three-Dimensional Ultrasonic Needle Tip Tracking with a Fiber-Optic Ultrasound Receiver
04:33

Three-Dimensional Ultrasonic Needle Tip Tracking with a Fiber-Optic Ultrasound Receiver

Published on: August 21, 2018

10.9K
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

8.0K

Related Experiment Videos

Last Updated: Feb 10, 2026

Surface Electromyographic Biofeedback as a Rehabilitation Tool for Patients with Global Brachial Plexus Injury Receiving Bionic Reconstruction
09:14

Surface Electromyographic Biofeedback as a Rehabilitation Tool for Patients with Global Brachial Plexus Injury Receiving Bionic Reconstruction

Published on: September 28, 2019

12.1K
Three-Dimensional Ultrasonic Needle Tip Tracking with a Fiber-Optic Ultrasound Receiver
04:33

Three-Dimensional Ultrasonic Needle Tip Tracking with a Fiber-Optic Ultrasound Receiver

Published on: August 21, 2018

10.9K
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

8.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trial Analysis

Background:

  • Niraparib is a PARP inhibitor for recurrent ovarian, fallopian tube, and primary peritoneal cancers.
  • The ENGOT-OV16/NOVA trial showed high rates of niraparib dose reduction (68.9%) and discontinuation (14.7%) due to adverse events, including 3.3% for thrombocytopenia.
  • A retrospective analysis aimed to identify predictors of dose reduction in niraparib treatment.

Purpose of the Study:

  • To identify clinical parameters predicting the need for niraparib dose reduction.
  • To determine optimal starting doses for niraparib based on patient characteristics.
  • To evaluate the impact of dose modification on treatment outcomes.

Main Methods:

  • Retrospective analysis of the ENGOT-OV16/NOVA trial safety population.
  • Utilized decision tree modeling to predict grade ≥3 thrombocytopenia within 30 days of niraparib initiation.
  • Identified key variables and cut-off points for predicting adverse events.

Main Results:

  • Baseline platelet count and body weight were significant predictors of grade ≥3 thrombocytopenia.
  • Patients with baseline body weight <77 kg or platelet count <150,000/µL experienced higher rates of thrombocytopenia.
  • Dose reduction to 200 mg or 100 mg did not negatively impact progression-free survival compared to the 300 mg starting dose.

Conclusions:

  • Patients with a baseline body weight <77 kg or platelet count <150,000/µL may benefit from a reduced starting dose of 200 mg/day niraparib.
  • Personalized dosing strategies could potentially mitigate adverse events like thrombocytopenia.
  • This approach may improve treatment adherence and tolerability in ovarian cancer patients receiving niraparib maintenance therapy.